title: [Nifekalant hydrochloride effective against perioperative ventricular tachycardia in patients with impaired left ventricular function].
abstract: Perioperative ventricular tachycardia (VT) was treated with nifekalant hydrochloride, a pure potassium channel blocker in 2 patients with low left ventricular ejection fraction (LVEF). The first patient is a 34-year-old woman, a chronic hemodialysis patient in whom severe aortic stenosis due to structural valvular deterioration of the previously implanted tissue valve was diagnosed with her LVEF of 26.9%. She underwent urgent redo aortic valve replacement with a mechanical valve. Postoperatively a sustained VT developed. After she received direct-current (DC) shock, nifekalant hydrochloride was administered. The 2nd patient is a 44-year-old man who presented with severe congestive heart failure. A coronary angiogram revealed triple vessel disease as well as decreased LVEF of 16% and ischemic mitral regurgitation. He underwent triple coronary artery bypass grafting and mitral ring annuloplasty. A VT developed requiring DC shock during hemostasis. Nifekalant hydrochloride was given immediately. In both patients, nifekalant hydrochloride was given intravenously in a dose of 0.3 mg/kg followed by a continuous intravenous infusion at a dose of 0.4 mg/kg/hr. Our experience shows nifekalant hydrochloride is effective against perioperative VT, especially in patients with impaired left ventricular function since it has mild positive inotropic effect.
authors.affiliation: Department of Cardiovascular Surgery, Oji General Hospital, Tomakomai, Japan.
authors.forename: Tasuya
authors.initials: T
authors.lastname: Murakami
authors.forename: Y
authors.initials: Y
authors.lastname: Makino
authors.forename: H
authors.initials: H
authors.lastname: Kato
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D019990:Perioperative Care; D011744:Pyrimidinones / Q000627:therapeutic use*; D017180:Tachycardia, Ventricular / Q000188:drug therapy* / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000889:Anti-Arrhythmia Agents; D011744:Pyrimidinones; C076259:nifekalant